For COVID-19 vaccine updates, please review our information guide. For patient eligibility and scheduling availability, please visit VaccineTogetherNY.org.

COVID-19 Vaccines: "Warp Speed" Needs Mind Melds, Not Warped Minds.

TitleCOVID-19 Vaccines: "Warp Speed" Needs Mind Melds, Not Warped Minds.
Publication TypeJournal Article
Year of Publication2020
AuthorsMoore JP, Klasse PJ
JournalJ Virol
Volume94
Issue17
Date Published2020 08 17
ISSN1098-5514
KeywordsAnimals, Antibodies, Neutralizing, Antibodies, Viral, Betacoronavirus, Coronavirus Infections, COVID-19, COVID-19 Vaccines, Humans, Immunogenicity, Vaccine, Middle East Respiratory Syndrome Coronavirus, Models, Animal, Pandemics, Pneumonia, Viral, SARS-CoV-2, Spike Glycoprotein, Coronavirus, Viral Vaccines
Abstract

In this review, we address issues that relate to the rapid "Warp Speed" development of vaccines to counter the COVID-19 pandemic. We review the antibody response that is triggered by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection of humans and how it may inform vaccine research. The isolation and properties of neutralizing monoclonal antibodies from COVID-19 patients provide additional information on what vaccines should try to elicit. The nature and longevity of the antibody response to coronaviruses are relevant to the potency and duration of vaccine-induced immunity. We summarize the immunogenicity of leading vaccine candidates tested to date in animals and humans and discuss the outcome and interpretation of virus challenge experiments in animals. By far the most immunogenic vaccine candidates for antibody responses are recombinant proteins, which were not included in the initial wave of Warp Speed immunogens. A substantial concern for SARS-CoV-2 vaccines is adverse events, which we review by considering what was seen in studies of SARS-CoV-1 and Middle East respiratory syndrome coronavirus (MERS-CoV) vaccines. We conclude by outlining the possible outcomes of the Warp Speed vaccine program, which range from the hoped-for rapid success to a catastrophic adverse influence on vaccine uptake generally.

DOI10.1128/JVI.01083-20
Alternate JournalJ Virol
PubMed ID32591466
PubMed Central IDPMC7431783
Grant ListP01 AI110657 / AI / NIAID NIH HHS / United States
R01 AI036082 / AI / NIAID NIH HHS / United States

Weill Cornell Medicine Microbiology and Immunology 1300 York Avenue, Box 62 New York, NY 10065 Phone: (212) 746-6505 Fax: (212) 746-8587